Ventyx Biosciences, Inc. (VTYX): Price and Financial Metrics

Ventyx Biosciences, Inc. (VTYX): $16.80

1.95 (+13.13%)

POWR Rating

Component Grades













Add VTYX to Watchlist
Sign Up

Industry: Biotech



in industry

VTYX Stock Price Chart Interactive Chart >

Price chart for VTYX

VTYX Price/Volume Stats

Current price $16.80 52-week high $26.00
Prev. close $14.85 52-week low $9.50
Day low $15.33 Volume 223,600
Day high $16.91 Avg. volume 135,838
50-day MA $13.60 Dividend yield N/A
200-day MA $0.00 Market Cap 854.28M

Ventyx Biosciences, Inc. (VTYX) Company Bio

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that has completed phase I clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases. In addition, the company develops CNS-penetrant NLRP3 inhibitors. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.

VTYX Latest News Stream

Event/Time News Detail
Loading, please wait...

VTYX Latest Social Stream

Loading social stream, please wait...

View Full VTYX Social Stream

Latest VTYX News From Around the Web

Below are the latest news stories about Ventyx Biosciences Inc that investors may wish to consider to help them evaluate VTYX as an investment opportunity.

We're Not Very Worried About Ventyx Biosciences' (NASDAQ:VTYX) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | January 21, 2022

Ventyx Biosciences Announces First Patient Dosed in a Phase 2 Clinical Trial of VTX002 for the Treatment of Moderate-to-Severe Ulcerative Colitis

VTX002 is an oral, peripherally-restricted, selective sphingosine 1 phosphate receptor 1 (S1P1) receptor modulator internally discovered and developed by the team at VentyxENCINITAS, Calif., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx” or the “Company”), a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders, announced today that the first patient has

Yahoo | December 6, 2021

Ventyx Biosciences (VTYX) Initiated with a Buy at LifeSci Capital

Ventyx Biosciences (VTYX – Research Report) received a Buy rating and a $40.00 price target from LifeSci Capital analyst Sam Slutsky on November 15. The company's shares closed last Monday at $21.76. According to, Slutsky is a 3-star analyst with an average return of 6.8% and a 41.9% success rate. Slutsky covers the Healthcare sector, focusing on stocks such as Catalyst Biosciences, Sierra Oncology, and BELLUS Health. Currently, the analyst consensus on Ventyx Biosciences is a Strong Buy with an average price target of $42.50, which is a 95.8% upside from current levels.

Carrie Williams on TipRanks | November 23, 2021

Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

ENCINITAS, Calif., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx” or the “Company”), a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders, announced today that Raju Mohan, Chief Executive Officer of Ventyx, will provide a company overview at the following upcoming investor conferences: Event: 4th Annual Evercore ISI HealthCONx ConferenceLocation: Virt

Yahoo | November 19, 2021

Ventyx Biosciences Reports Third Quarter Financial Results and Provides Business Update

Wholly-owned pipeline with three clinical-stage programs targeting significant inflammatory and immunology disease markets Dosing initiated in a multiple-ascending dose (MAD) Phase 1 trial for VTX958, an oral, selective tyrosine kinase type 2 (TYK2) inhibitor, and a Phase 1 trial for VTX2735, an oral Nod-like receptor protein 3 (NLRP3) inhibitor Completed upsized initial public offering (IPO) of common stock, raising approximately $174.3 million in gross proceeds, including full exercise of unde

Yahoo | November 17, 2021

Read More 'VTYX' Stories Here

VTYX Price Returns

1-mo N/A
3-mo 43.10%
6-mo -21.42%
1-year N/A
3-year N/A
5-year N/A
YTD -15.41%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7591 seconds.